Latest Breaking News On - Degenerative disc - Page 6 : comparemela.com

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Appendix 4C Quarterly Activity Report Mesoblast LimitedApril 30, 2021 GMT NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its pipeline of late-stage product candidates, and an activity report for the third quarter ended March 31, 2021. “We are very excited about the top-line results announced today from the trial of remestemcel-L in patients on mechanical ventilation due to COVID-19. These showed that remestemcel-L reduced mortality through 60 days in the pre-specified population under 65 years old, particularly when used with dexamethasone as part of standard of care. This has the potential to make a substantial impact in outcomes for this critical patient population,” said Silviu Itescu, Chief Executive of Mesoblast.

United statesPhilipj facchinaSilviu itescuKristen bothwellPaul hughesYork heart associationDrug administrationAustralian securities exchangeOncologic drugs advisory committeeMesoblast limited nasdaqCorporate communications investorsSurgcenter developmentChief executiveChief strategy officerMesoblast boardRespiratory distress syndrome